Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069487 | 0.84 | DPP4 (0.45) | DPP4LRRK2PRKCQMAP4K1 | |
| SCHEMBL3071649 | 0.83 | DPP4 (0.46) | DPP4IRAK4 | |
| SCHEMBL13139862 | 0.75 | DPP4 (0.54) | DPP4DPP8 | |
| SCHEMBL3073729 | 0.75 | DPP4 (0.54) | DPP4DPP8 | |
| SCHEMBL13236880 | 0.75 | DPP4 (0.54) | DPP4DPP8 | |
| SCHEMBL13139851 | 0.69 | DPP4 (0.50) | DPP4DPP8 | |
| SCHEMBL3065092 | 0.69 | DPP4 (0.50) | DPP4DPP8 | |
| SCHEMBL3063725 | 0.68 | DPP4 (0.48) | DPP4 | |
| SCHEMBL3071647 | 0.64 | DPP4 (0.50) | DPP4 | |
| SCHEMBL13139849 | 0.64 | DPP4 (0.50) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699777-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2012-12-12 | — | — | EP | claimed |
| US-7790734-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | claimed |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885IRAK4 1855/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.